# Biovie Inc.: financial statements, quarterly

BIVI · Nasdaq · CIK 1580149 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/bivi.md) · [Financials](/companies/bivi/financials.md) · [Filings](/companies/bivi/filings.md) · [Insiders](/companies/bivi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bivi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [8.9](/filings/0001520138-24-000425.md) | [6.5](/filings/0001520138-25-000056.md) | [5.7](/filings/0001520138-25-000144.md) | [2.1 d](/filings/0001520138-25-000268.md) | [2.0](/filings/0001520138-25-000343.md) | [4.7](/filings/0001520138-26-000052.md) | [1.3](/filings/0001520138-26-000154.md) | [1.2 d](/filings/0001520138-26-000332.md) | [2.9](/filings/0001520138-25-000343.md) | [4.3](/filings/0001520138-26-000052.md) | [3.2](/filings/0001520138-26-000154.md) | [3.6 d](/filings/0001520138-26-000332.md) |
| Selling, general and administrative | $m | [1.9](/filings/0001520138-24-000425.md) | [2.3](/filings/0001520138-25-000056.md) | [2.0](/filings/0001520138-25-000144.md) | [2.7 d](/filings/0001520138-25-000268.md) | [2.1](/filings/0001520138-25-000343.md) | [2.5](/filings/0001520138-25-000056.md) | [1.6](/filings/0001520138-25-000144.md) | [2.4 d](/filings/0001520138-25-000268.md) | [2.3](/filings/0001520138-25-000343.md) | not reported | not reported | not reported |
| Operating income | $m | [(10.9)](/filings/0001520138-24-000425.md) | [(8.8)](/filings/0001520138-25-000056.md) | [(7.7)](/filings/0001520138-25-000144.md) | [(4.8) d](/filings/0001520138-25-000268.md) | [(4.1)](/filings/0001520138-25-000343.md) | [(7.3)](/filings/0001520138-26-000052.md) | [(3.0)](/filings/0001520138-26-000154.md) | [(3.7) d](/filings/0001520138-26-000332.md) | [(5.3)](/filings/0001520138-25-000343.md) | [(6.3)](/filings/0001520138-26-000052.md) | [(5.4)](/filings/0001520138-26-000154.md) | [(5.7) d](/filings/0001520138-26-000332.md) |
| Interest expense | $m | [1.0](/filings/0001520138-24-000425.md) | [0.8](/filings/0001520138-24-000069.md) | [0.6](/filings/0001520138-24-000204.md) | [0.4 d](/filings/0001520138-24-000324.md) | [0.3](/filings/0001520138-24-000425.md) | [0.1](/filings/0001520138-26-000052.md) | [0.0](/filings/0001520138-26-000154.md) | [0.0 d](/filings/0001520138-26-000332.md) | [0.0](/filings/0001520138-25-000343.md) | [0.0](/filings/0001520138-26-000052.md) | [0.0](/filings/0001520138-26-000154.md) | [0.0 d](/filings/0001520138-26-000332.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(10.7)](/filings/0001520138-25-000144.md) | [(8.4)](/filings/0001520138-25-000144.md) | [(8.1)](/filings/0001520138-25-000144.md) | [(4.9) d](/filings/0001520138-25-000268.md) | [(4.2)](/filings/0001520138-26-000154.md) | [(7.1)](/filings/0001520138-26-000154.md) | [(2.8)](/filings/0001520138-26-000154.md) | [(3.5) d](/filings/0001520138-26-000332.md) | [(5.1)](/filings/0001520138-26-000154.md) | [(6.1)](/filings/0001520138-26-000154.md) | [(5.3)](/filings/0001520138-26-000154.md) | [(5.6) d](/filings/0001520138-26-000332.md) |
| Diluted EPS | $ per share | [(2.92)](/filings/0001520138-24-000425.md) | [(2.20)](/filings/0001520138-25-000056.md) | [(2.00)](/filings/0001520138-25-000144.md) | not reported | [(7.00)](/filings/0001520138-25-000343.md) | [(4.55)](/filings/0001520138-26-000052.md) | [(1.51)](/filings/0001520138-26-000154.md) | not reported | [(0.98)](/filings/0001520138-25-000343.md) | [(0.77)](/filings/0001520138-26-000052.md) | [(0.70)](/filings/0001520138-26-000154.md) | not reported |
| Basic EPS | $ per share | [(2.92)](/filings/0001520138-24-000425.md) | [(2.20)](/filings/0001520138-25-000056.md) | [(2.00)](/filings/0001520138-25-000144.md) | not reported | [(7.00)](/filings/0001520138-25-000343.md) | [(4.55)](/filings/0001520138-26-000052.md) | [(1.51)](/filings/0001520138-26-000154.md) | not reported | [(0.98)](/filings/0001520138-25-000343.md) | [(0.77)](/filings/0001520138-26-000052.md) | [(0.70)](/filings/0001520138-26-000154.md) | not reported |

- Revenue: not reported
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [21.2](/filings/0001520138-23-000473.md) | [20.2](/filings/0001520138-24-000069.md) | [30.4](/filings/0001520138-24-000204.md) | [23.8](/filings/0001520138-25-000268.md) | [20.0](/filings/0001520138-24-000425.md) | [24.4](/filings/0001520138-25-000056.md) | [23.2](/filings/0001520138-25-000144.md) | [17.5](/filings/0001520138-26-000332.md) | [25.0](/filings/0001520138-25-000343.md) | [20.5](/filings/0001520138-26-000052.md) | [13.1](/filings/0001520138-26-000154.md) | [9.0](/filings/0001520138-26-000332.md) |
| Current assets | $m | [22.8](/filings/0001520138-23-000473.md) | [20.6](/filings/0001520138-24-000069.md) | [30.5](/filings/0001520138-24-000204.md) | [24.0](/filings/0001520138-25-000268.md) | [20.2](/filings/0001520138-24-000425.md) | [24.7](/filings/0001520138-25-000056.md) | [23.7](/filings/0001520138-25-000144.md) | [20.7](/filings/0001520138-26-000332.md) | [26.0](/filings/0001520138-25-000343.md) | [21.8](/filings/0001520138-26-000052.md) | [16.9](/filings/0001520138-26-000154.md) | [13.6](/filings/0001520138-26-000332.md) |
| Total assets | $m | [23.8](/filings/0001520138-23-000473.md) | [21.5](/filings/0001520138-24-000069.md) | [31.8](/filings/0001520138-24-000204.md) | [25.2](/filings/0001520138-25-000268.md) | [21.2](/filings/0001520138-24-000425.md) | [25.7](/filings/0001520138-25-000056.md) | [24.7](/filings/0001520138-25-000144.md) | [21.6](/filings/0001520138-26-000332.md) | [26.8](/filings/0001520138-25-000343.md) | [22.5](/filings/0001520138-26-000052.md) | [17.5](/filings/0001520138-26-000154.md) | [14.3](/filings/0001520138-26-000332.md) |
| Current liabilities | $m | [13.2](/filings/0001520138-23-000473.md) | [14.0](/filings/0001520138-24-000069.md) | [12.5](/filings/0001520138-24-000204.md) | [9.4](/filings/0001520138-25-000268.md) | [6.8](/filings/0001520138-24-000425.md) | [1.5](/filings/0001520138-25-000056.md) | [2.5](/filings/0001520138-25-000144.md) | [2.3](/filings/0001520138-26-000332.md) | [1.6](/filings/0001520138-25-000343.md) | [3.0](/filings/0001520138-26-000052.md) | [1.7](/filings/0001520138-26-000154.md) | [3.8](/filings/0001520138-26-000332.md) |
| Total liabilities | $m | [16.2](/filings/0001520138-23-000473.md) | [14.0](/filings/0001520138-24-000069.md) | [12.8](/filings/0001520138-24-000204.md) | [9.7](/filings/0001520138-25-000268.md) | [7.2](/filings/0001520138-24-000425.md) | [1.8](/filings/0001520138-25-000056.md) | [2.8](/filings/0001520138-25-000144.md) | [2.6](/filings/0001520138-26-000332.md) | [1.9](/filings/0001520138-25-000343.md) | [3.2](/filings/0001520138-26-000052.md) | [1.9](/filings/0001520138-26-000154.md) | [4.0](/filings/0001520138-26-000332.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [7.5](/filings/0001520138-25-000144.md) | [7.5](/filings/0001520138-25-000144.md) | [18.9](/filings/0001520138-25-000144.md) | [15.5](/filings/0001520138-26-000332.md) | [14.1](/filings/0001520138-26-000154.md) | [23.9](/filings/0001520138-26-000154.md) | [21.8](/filings/0001520138-26-000154.md) | [19.0](/filings/0001520138-26-000332.md) | [24.9](/filings/0001520138-26-000154.md) | [19.3](/filings/0001520138-26-000154.md) | [15.6](/filings/0001520138-26-000154.md) | [10.3](/filings/0001520138-26-000332.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.2)](/filings/0001520138-24-000425.md) | [(5.9) d](/filings/0001520138-25-000056.md) | [(5.9) d](/filings/0001520138-25-000144.md) | [(4.0) d](/filings/0001520138-25-000268.md) | [(3.6)](/filings/0001520138-25-000343.md) | [(8.6) d](/filings/0001520138-26-000052.md) | [(1.3) d](/filings/0001520138-26-000154.md) | [(5.6) d](/filings/0001520138-26-000332.md) | [(3.0)](/filings/0001520138-25-000343.md) | [(4.4) d](/filings/0001520138-26-000052.md) | [(7.4) d](/filings/0001520138-26-000154.md) | [(4.1) d](/filings/0001520138-26-000332.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [27.2](/filings/0001520138-23-000473.md) | [31.2](/filings/0001520138-24-000069.md) | [35.3](/filings/0001520138-24-000204.md) | [3.7](/filings/0001520138-24-000425.md) | [3.8](/filings/0001520138-25-000056.md) | [4.5](/filings/0001520138-25-000144.md) | [0.6](/filings/0001520138-25-000343.md) | [1.6](/filings/0001520138-26-000052.md) | [1.9](/filings/0001520138-26-000154.md) | [5.2](/filings/0001520138-25-000343.md) | [7.9](/filings/0001520138-26-000052.md) | [7.5](/filings/0001520138-26-000154.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 7,542,638 at 2026-08-10, from the cover of the [10-K filed 2026-08-13](/filings/0001520138-26-000332.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.